U.S. FDA extends action date for ELIQUIS® (apixaban) by three months
29 February 2012 | By Pfizer
The U.S. FDA has extended the action date by three months for the NDA for Eliquis® (apixaban)...
List view / Grid view
News
Abbott and Galapagos announce global collaboration for novel oral therapy, GLPG0634, in Phase II
29 February 2012 | By Abbott
Abbott and Galapagos have entered into a global collaboration...
Two Phase III studies of Novartis drug INC424 published in NEJM show significant clinical benefit for patients with myelofibrosis
29 February 2012 | By Novartis
Results of the COMFORT-I and COMFORT-II trials show INC424 significantly reduced disease burden in patients with myelofibrosis...
Lilly introduces global ‘Innovation Starts Here’ initiative to foster innovation and quality science
28 February 2012 | By Eli Lilly and Company
Lilly award programs also further research and development investment in Europe...
FDA approves AVONEX PEN and dose titration regimen
28 February 2012 | By
Dosing enhancements may improve treatment experience for patients receiving AVONEX® (interferon beta-1a) for MS...
Biogen Idec submits application to FDA for approval of oral BG-12 to treat multiple sclerosis
28 February 2012 | By Biogen Idec
EMA submission anticipated within the coming days...
Amgen and European Schoolnet launch new professional development initiative for life science teachers
28 February 2012 | By Amgen
Amgen & European Schoolnet launched “Amgen Science Teacher Training Initiative”...
Ranbaxy crosses $2bn in global sales
28 February 2012 | By Daiichi Sankyo Co., Ltd
The Board of Directors of Ranbaxy Laboratories Limited, took on record the audited results for the Quarter and Year ended December 31, 2011...
Bristol-Myers Squibb and Duke Translational Medicine Institute form strategic relationship to broaden interactions
28 February 2012 | By Bristol-Myers Squibb Company
First project will be to develop and implement protocol for Phase II study in IPF...
Lundbeck strengthens ownership of desmoteplase by acquiring Paion’s remaining rights
28 February 2012 | By H. Lundbeck A/S (Lundbeck)
Lundbeck acquires Paion's remaining rights to desmoteplase for EUR 20.1 million thereby further strengthening the control over desmoteplase...
Merck provides information on FDA post-marketing requirement for Sitagliptin
28 February 2012 | By Merck
Merck received a Warning Letter from the U.S. FDA relating to JANUVIA (sitagliptin) and JANUMET (sitagliptin/metformin HCl)...
Takeda announces acceptance of European Marketing Authorisation application for Peginesatide
27 February 2012 | By Weber Shandwick
An investigational compound for the treatment of anemia associated with CKD...
Sanofi and the Institut Pasteur create four prestigious awards to support innovative biomedical research
27 February 2012 | By Sanofi
The creation of the Sanofi-Institut Pasteur Awards announced...
Roche extends tender offer for Illumina
27 February 2012 | By Roche
Roche has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc. at a price of $44.50 per share...
European Commission approves new label for Novartis drug Glivec®
27 February 2012 | By Novartis
The European Commission has approved an update to the Glivec® (imatinib)* label...
